NEW PROCEDURE FOR THE DETECTION OF COMPLEMENT DEFICIENCY BY ELISA - ANALYSIS OF ACTIVATION PATHWAYS AND CIRCUMVENTION OF RHEUMATOID-FACTOR INFLUENCE

被引:29
作者
FREDRIKSON, GN [1 ]
TRUEDSSON, L [1 ]
SJOHOLM, AG [1 ]
机构
[1] LUND UNIV,DEPT MED MICROBIOL,CLIN IMMUNOL SECT,S-22362 LUND,SWEDEN
关键词
COMPLEMENT; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT FIXATION TEST; ELISA; PROPERDIN;
D O I
10.1016/0022-1759(93)90367-G
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A procedure using enzyme-linked immunosorbent assays for the assessment of complement function has been evaluated. The sera investigated were incubated in microtiter plates with solid-phase complement activators. Human polyclonal IgG or monoclonal IgM were used for classical activation pathway assays and Salmonella typhosa lipopolysaccharide (LPS) for alternative activation pathway assays. The analysis focussed on deposition of C9 and properdin as detected with enzyme-conjugated antibodies. In an attempt to avoid spurious results due to rheumatoid factors in patient sera, monoclonal mouse and chicken antibodies were unsuccessfully tested as indicator reagents in the assay with solid-phase IgG. However, the use of solid-phase IgM as an activator completely circumvented the influence of rheumatoid factors. With solid-phase IgG or IgM, properdin deposition occurred in the absence of factor D. A combination of assays is suggested for diagnostic purposes: IgM-coated plates with detection of bound C9 and properdin for the classical pathway and LPS-coated plates with detection of bound properdin for the alternative pathway. The procedure distingished between defects of the classical activation pathway (C1, C4, C2), the alternative activation pathway (C3, factor B, factor D, properdin) and the terminal components (C5-C9). This analytical approach may be useful for detection of inherited complement deficiency and the assessment of complement function in acquired complement deficiency states.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 29 条
[1]  
BAATRUP G, 1986, SCAND J IMMUNOL, V23, P397
[2]  
BAATRUP G, 1988, J CLIN LAB IMMUNOL, V26, P73
[3]   COMPLEMENT DEFICIENCIES [J].
COLTEN, HR ;
ROSEN, FS .
ANNUAL REVIEW OF IMMUNOLOGY, 1992, 10 :809-834
[4]   ANALYSIS OF THE INTERACTIONS BETWEEN PROPERDIN, THE 3RD COMPONENT OF COMPLEMENT (C-3), AND ITS PHYSIOLOGICAL ACTIVATION PRODUCTS [J].
FARRIES, TC ;
LACHMANN, PJ ;
HARRISON, RA .
BIOCHEMICAL JOURNAL, 1988, 252 (01) :47-54
[5]   ANALYSIS OF THE INTERACTION BETWEEN PROPERDIN AND FACTOR-B, COMPONENTS OF THE ALTERNATIVE-PATHWAY C-3 CONVERTASE OF COMPLEMENT [J].
FARRIES, TC ;
LACHMANN, PJ ;
HARRISON, RA .
BIOCHEMICAL JOURNAL, 1988, 253 (03) :667-675
[6]   INFECTIOUS-DISEASES ASSOCIATED WITH COMPLEMENT DEFICIENCIES [J].
FIGUEROA, JE ;
DENSEN, P .
CLINICAL MICROBIOLOGY REVIEWS, 1991, 4 (03) :359-395
[7]   DETECTION AND ANALYSIS OF INBORN AND ACQUIRED COMPLEMENT ABNORMALITIES [J].
GEWURZ, AT ;
LINT, TF ;
IMHERR, SM ;
GARBER, SS ;
GEWURZ, H .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1982, 23 (02) :297-311
[8]  
Grubb R., 1970, GENETIC MARKERS HUMA
[9]  
HARRISON RA, 1986, HDB EXPT IMMUNOLOGY, V1, P39
[10]  
HASSAN J, 1992, CLIN EXP IMMUNOL, V89, P423